United Kingdom Cardiovascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

The UK cardiovascular devices market size is USD 2.55 billion in 2025 and is projected to reach USD 3.48 billion by 2030, expanding at a 6.45% CAGR during the forecast period.

Robust NHS capital funding, virtual ward roll-outs and rapid uptake of AI-enabled diagnostics are sustaining momentum even as post-Brexit regulatory duplication adds cost and complexity. Demand is concentrating around minimally invasive systems that shorten hospital stays, with transcatheter valve and pulsed-field ablation platforms becoming mainstay therapies. Supply-chain pressures have encouraged domestic manufacturing initiatives, while sustainability mandates are spurring investment in recyclable single-use catheters. Competitive dynamics remain intense, with strategic acquisitions and AI-centric product launches reshaping technology leadership.

United Kingdom Cardiovascular Devices Market Trends and Insights

NHS Long-Term Plan Funding Boost for Cardiac Networks Accelerating Device Adoption

Targeted investments channelled through the GBP 25.7 billion NHS uplift for 2024-2025 are modernising cardiac networks and enabling faster technology rotation . Allocating GBP 1.5 billion to surgical hubs and GBP 70 million to advanced radiotherapy suites gives trusts the capacity to clear procedure backlogs while integrating novel devices. The NHS 10-Year Plan ties procurement to measurable outcomes, favouring vendors with strong clinical-evidence files. Integrated care systems encourage cross-trust purchasing, increasing order volumes and shortening adoption cycles by up to two years. These funding streams thus reinforce first-mover advantages for innovators with proven value propositions.

Rapid Uptake of Remote Cardiac Monitoring under NHS "Virtual Wards" Programme

NHS England aims to deliver 50,000 virtual-ward beds by 2025, fundamentally redesigning cardiac care pathways. Early pilots such as the Northern Care Alliance's 500-bed model cut acute admissions by 30%, validating the service design at scale. NICE guidance endorsing HeartLogic and TriageHF technologies, which reduce heart-failure hospitalisations by up to 72%, further underpins rapid diffusion. Academic studies at Imperial College Healthcare show 76% fewer readmissions when tele-monitoring complements standard therapy. Savings of GBP 1,958 per patient strengthen the business case, opening new revenue channels for device makers aligned with NHS digital architecture.

High Failure-Recall Rates of Certain Stent Models Eroding Clinician Confidence

Class I recalls involving Boston Scientific's Accolade pacemakers and Abbott's Assurity series have shaken trust, prompting closer scrutiny of new technologies. MHRA reforms effective June 2025 demand active surveillance and faster incident reporting, raising compliance costs and delaying launches. Adverse publicity extends beyond recalled SKUs, dampening uptake across adjacent product categories. Clinicians now seek extensive post-market data before switching platforms, lengthening sales cycles and elevating barriers for SMEs.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Backlog of Elective Cardiac Procedures Driving Shift to Minimally Invasive Devices
2. Increasing Prevalence of Atrial Fibrillation in Ageing UK Population Raising Demand for Rhythm-Management Devices
3. NHS Workforce Shortage Constraining Equipment Replacement Cycles

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Therapeutic and surgical platforms generated 58.20% of 2024 revenues, sustained by well-resourced cardiac centres performing high-value interventions. Uptake of ultrathin drug-eluting stents and TAVR systems illustrates how procedural efficiency steers purchasing decisions. Abbott's AVEIR leadless pacemaker, now under breakthrough-device designation, shows the innovation premium vendors can command .

Diagnostic and monitoring solutions, though smaller today, are projected to grow at a 6.98% CAGR through 2030 as prevention and remote care take centre stage. AI-enabled ECG devices that rival 12-lead hospital units underscore this momentum. Virtual-ward expansion embeds remote telemetry in standard care pathways, lifting recurring revenue from cloud analytics. Consequently, the UK cardiovascular devices market size for diagnostics is on path to outstrip therapeutics in growth pace, reshaping revenue mixes over the decade.

The UK Cardiovascular Devices Market Report is Segmented by Product Type (Diagnostic & Monitoring Devices, Therapeutic & Surgical Devices), Application (Coronary Artery Disease, Arrhythmia & Conduction Disorders, Heart Failure & Cardiomyopathy, Structural & Congenital Heart Defects, and More), End User (Hospitals & Cardiac Centres, Ambulatory Surgical Centres, and More). The Market Forecasts are Provided in Terms of Value (USD).

List of Companies Covered in this Report:

1. Medtronic
2. Abbott Laboratories
3. Boston Scientific
4. Edward Lifesciences
5. Koninklijke Philips
6. Siemens Healthineers
7. Johnson & Johnson (Biosense Webster & Cordis)
8. GE Healthcare Technologies Inc.
9. Terumo
10. B. Braun
11. BIOTRONIK
12. LivaNova
13. MicroPort
14. Cook Group
15. W. L. Gore & Associates
16. Getinge AB (Maquet)
17. Merit Medical Systems
18. Shockwave Medical Inc.
19. Penumbra
20. SynCardia Systems
21. Nipro
22. Corin Group PLC

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support